Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.57 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.57 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8110360 | 0.92 | CHRM3 (0.66) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6941984 | 0.92 | CHRM3 (0.66) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL11539098 | 0.90 | CHRM3 (0.64) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL17967828 | 0.83 | CHRM2 (0.59) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL31618492 | 0.81 | CXCR4 (0.67) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12013923 | 0.79 | CHRM2 (0.68) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL27142753 | 0.78 | KDM4E (0.63) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL27140915 | 0.77 | KDM4E (0.61) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4187783 | 0.76 | MEN1 (0.48) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8821609 | 0.76 | LMNA (0.62) | CXCR4CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CXCR4 7/4885CHRM2 1996/4885CHRM4 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.